Escherichia Coli Infections
12
0
0
8
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
16.7%
2 terminated out of 12 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (12)
Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria
Detection of Biofilm Among Uropathogenic Escherichia Coli Clinical Isolates in Suez Canal University Hospitals
Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients
Effects of Nutritional Fat on the Growth of Intestinal E. Coli
Epidemiology of ST131 in Besançon University Hospital
Characteristics of Lower Respiratory Tract Escherichia Coli Isolates in Mechanically Ventilated Intensive Care Patients
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
Enteroaggregative E.Coli (EAEC)
Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms
Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4
Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units